Danaher Co. (NYSE:DHR) Shares Sold by Stableford Capital II LLC

Stableford Capital II LLC cut its holdings in Danaher Co. (NYSE:DHR) by 0.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,331 shares of the conglomerate’s stock after selling 45 shares during the quarter. Stableford Capital II LLC’s holdings in Danaher were worth $1,224,000 at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of DHR. Heck Capital Advisors LLC acquired a new stake in shares of Danaher in the fourth quarter worth approximately $27,000. Decker Retirement Planning Inc. acquired a new position in shares of Danaher in the 4th quarter valued at $31,000. Teachers Insurance & Annuity Association of America purchased a new stake in shares of Danaher during the 3rd quarter valued at $39,000. MidAtlantic Capital Management Inc. acquired a new stake in shares of Danaher during the 3rd quarter worth $40,000. Finally, FSA Wealth Management LLC purchased a new position in shares of Danaher in the 3rd quarter worth $50,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Trading Down 0.2 %

DHR opened at $222.56 on Friday. The stock has a market capitalization of $160.75 billion, a PE ratio of 42.15, a P/E/G ratio of 4.22 and a beta of 0.83. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. Danaher Co. has a 12-month low of $221.34 and a 12-month high of $281.70. The firm’s fifty day moving average price is $235.40 and its 200 day moving average price is $253.07.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, hitting the consensus estimate of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.72%. During the same quarter in the previous year, the business earned $2.09 EPS. As a group, research analysts expect that Danaher Co. will post 8.15 EPS for the current fiscal year.

Danaher Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, January 31st. Stockholders of record on Friday, December 27th were issued a $0.27 dividend. The ex-dividend date of this dividend was Friday, December 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.49%. Danaher’s dividend payout ratio (DPR) is 20.45%.

Analyst Ratings Changes

Several brokerages have commented on DHR. UBS Group dropped their price target on Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a research note on Wednesday, October 23rd. KeyCorp raised their price target on shares of Danaher from $290.00 to $310.00 and gave the company an “overweight” rating in a report on Wednesday, October 23rd. JPMorgan Chase & Co. decreased their price objective on shares of Danaher from $310.00 to $300.00 and set an “overweight” rating for the company in a research note on Tuesday. Stifel Nicolaus raised their target price on shares of Danaher from $250.00 to $265.00 and gave the company a “hold” rating in a research note on Wednesday, October 23rd. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $277.00 price target (down from $299.00) on shares of Danaher in a research report on Thursday. Six investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $278.00.

Insider Activity at Danaher

In related news, SVP Brian W. Ellis sold 5,700 shares of the stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the sale, the senior vice president now owns 20,230 shares in the company, valued at $4,534,149.90. This represents a 21.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 11.10% of the company’s stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.